Navigation Links
Menopause Drug Tied to Breast Cancer Recurrence
Date:2/17/2009

Dutch study of tibolone, also used for osteoporosis but not available in U.S., was stopped early due to increased risk,,

TUESDAY, Feb. 17 (HealthDay News) -- A large study of tibolone, a drug used to treat menopausal symptoms and to prevent osteoporosis, was halted early after researchers found that the synthetic steroid significantly increased the risk of recurrent breast cancer among survivors of the disease.

Tibolone isn't available in the United States but is approved in 90 countries for easing menopausal symptoms and approved in 55 countries as an osteoporosis treatment. Many breast cancer patients use the drug to counteract the effects of early menopause caused by cancer treatments.

The new findings indicate that the drug should not be prescribed to any woman with known, past, or suspected breast cancer, said Prof. Peter Kenemans, of the VU University Medical Center in Amsterdam, Netherlands, and colleagues.

Tibolone acts like the female hormones estrogen and progesterone in relieving menopausal symptoms. But, unlike estrogen and progesterone, it has been believed that tibolone would reduce the risk of some cancers.

This study included almost 3,100 women who'd had surgery for breast cancer. The women were randomly assigned to receive either 2.5 milligrams of tibolone a day or a placebo. The women's mean age at the start of the study was 52.7 years and the mean time since surgery was 2.7 years.

Among the 1,556 women taking tibolone, 237 (15.2 percent) experienced a cancer recurrence, compared with 165 (10.7 percent) of the 1,542 women taking the placebo. That meant that women taking tibolone had a 40 percent increased risk of recurrent cancer. The researchers also found that 70 percent of the recurrences among the women taking tibolone were distant metastases, which are usually fatal.

This increased risk associated with tibolone was so serious that the study was halted six months
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
2. Study shows younger women with endometrial cancer can safely keep ovaries, avoid early menopause
3. Omega-3s ease depressive symptoms related to menopause
4. Is rapid transition through menopause linked to earlier onset of heart disease?
5. Reduced breast cancer risk: Physical activity after menopause pays off
6. Male Menopause Treatment Provider, ReNEW MAN, Increases Online Presence
7. Why women should eat less, move more and consider wearing transdermal HRT patches during menopause
8. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
9. New hormone data can predict menopause within a year
10. Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines
11. Changes in sex steroids associated with menopause
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Menopause Drug Tied to Breast Cancer Recurrence
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous ... of top bridesmaid dresses online. At the moment, ... up to 52% off. According to the company’s senior spokesman, ... , The company’s stock is limited. Those who are ... store as soon as possible. All its products are delicately ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... 2014 The Judicial Panel on Multidistrict ... replacement therapy caused strokes, heart attacks, and other injuries ... Matthew F. Kennelly as the transferee judge and ordered ... Chicago-based federal court. , As one of his first ... committees of attorneys who will move the litigation forward ...
(Date:8/1/2014)... San Diego School of Medicine report that dietary capsaicin ... chronic activation of a receptor on cells lining the ... the risk of colorectal tumors. , The findings are ... The Journal of Clinical Investigation . , The receptor ... sensory neurons, where it acts as a sentinel for ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Study reveals one reason brain tumors are more common in men 2
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... www.stressballsuk.com ... points to an economic upturn and possibly the beginning of the end of the credit ... (PRWEB) March 2, ... to an economic upturn and possibly the beginning of the end of the credit crunch., ...
... ... event focusing on insights into the exploding field of neuroscience, what this means for ... the most effective ways to motivate and generate transformation in organisations – all leading ... ...
... ... to fill the gap in poor physician adherence to low back pain management guidelines with the ... ... for the iPhone platform this week to help bridge an expensive health care gap. The ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
(Date:8/1/2014)... PLAINFIELD, N.J. , Aug. 1, 2014  PTC ... that on July 31, 2014 it approved non-statutory stock ... its common stock to seven new employees. The awards ... as a component of our new hires, employment compensation. ... Compensation Committee on July 31, 2014 and are being ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health ... to speak a second language. Clinical efficacy is no ... established under the ACA like PCORI are directing roughly ... variety of new entities and environments, the federal healthcare ... the new language of outcomes and managed markets to ...
(Date:8/1/2014)... and NEW YORK , ... VRX) and Pershing Square Capital Management, L.P. today responded ... Inc. (NYSE: AGN ) in California.  The ... regarding the tender offer rules.  Allergan,s ... to interfere with shareholders, efforts to call a special ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) ... ) and Cephalon, Inc. (NASADQ: CEPH) on their announcement that ... to the news, Valeant has withdrawn its consent solicitation. ... for Cephalon stockholders and we are pleased that Teva has ...
... Solutions, Inc. (OTCQB: VHSLD) announced that it will begin ... Financial Industry Regulatory Authority has approved a change in ... ticker change has gone into effect for the trading ... the "D" will be removed from the ticker symbol ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change 2
Designed for use during surgical procedures under fluoroscopy. A very practical unit, the frames superior design eliminates problems associated with imaging....
Low temp, micro fine tip, patented Aaron RAM cauteries....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: